Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin

Clinical Microbiology and Infection

Volumn 8, Issue 10, 2002, Pages 671-675

  Maraha, B ^a,d   Van Halteren, J ^a   Verzijl, J M ^b   Wintermans, R G F ^c   Buiting, A G M ^a  

^a CPRLab   (Netherlands)

^b GGZ Midden Brabant   (Netherlands)

^c Franciscus Hospital   (Netherlands)

^d ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

Decolonization; MRSA; Vancomycin

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; OXACILLIN; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN; VANCOMYCIN CP;

ABDOMINAL PAIN; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FLATULENCE; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; OINTMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING TEST; STAPHYLOCOCCUS INFECTION; STOMATITIS; XEROSTOMIA;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0036803169     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00404.x     Document Type: Article

References (31)

1. Mulligan ME, Murray-Leisure KA, Ribner BS et al. Methicillin-resistant Staphylococcus aureus: a consensus review of microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94: 313-28.
2. Fraise AP. Guidelines for the control of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 287-9.
3. Arathoon EG, Hamilton JR, Hench CE, Stevens DA. Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrob Agents Chemother 1990; 34: 1655-9.
4. Bitar CM, Mayhall CG, Lamb VA, Bradshaw TJ, Spadora AC, Dalton HP. Outbreak due to methicillin-resistant Staphylococcus aureus: epidemiology and eradication of the resistant strain from the hospital. Infect Control 1987; 8: 15-23.
5. Darouiche R, Wright C, Hamill R, Koza M, Lewis D, Markowski J. Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin. Antimicrob Agents Chemother 1991; 35: 1612-15.
6. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1412-16.
7. Parras F, Del Carmen Guerrero M, Bouza E et al. Comparative study of mupirocin and oral cotrimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 175-9.
8. Peterson LR, Quick JN, Jansen B et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Arch Intern Med 1990; 150: 2151-5.
9. Valls V, Gomez-Herruz P, Gonzalez-Palacios R, Cuadros JA, Romanyk JP, Ena J. Long-term efficacy of a program to control methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1994; 13: 90-5.
10. Walsh TJ, Standiford HC, Reboli AC et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993; 37: 1334-42.
11. Hill RLR, Duckworth GJ, Casewell NW. Elimination of nasal carriage of methicillin resistant Staphylococcus aureus with mupirocin during a hospital outbreak. J Antimicrob Chemother 1998; 22: 377-84.
12. Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med 1993; 94: 371-8.
13. Duckworth G, Cookson B, Humphreys H, Heathcock R. Working party report. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J Hosp Infect 1998; 39: 253-90.
14. Konishi T, Idezuki Y, Kobayashi H et al. Oral vancomycin hydrochloride therapy for postoperative methicillin-resistant Staphylococcus aureus enteritis. Surg Today 1997; 27: 826-32.
15. Bryan CS, Wilson RS, Meade P, Sill LG. Topical antibiotic ointments for staphylococcal nasal carriers: survey of current practices and comparison of bacitracin and vancomycin ointments. Infect Control 1981; 1: 153-6.
16. Gradon JD, Wu EH, Lutwick LI. Aerosolized vancomycin therapy facilitating nursing home placement. Ann Pharmacother 1992; 26: 209-10.
17. Weathers L, Riggs D, Santeiro M, Weibley RE. Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 1990; 9: 220-1.
18. Kelly CP, Pothulakis C, La Mont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
19. de Lalla F, Nicolin R, Rinaldi E et al. Prospective study of oral teicoplanin versus vancomycin for therapy of pseudomembraneous collitis and Clostridium difficle-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 2192-6.
20. Dudley MN, McLaughlin PC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs. vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986; 146: 1101-4.
21. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324-33.
22. Fekety R, Silva R, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 15-19.
23. Wenisch C, Parschalk B, Hasenhundl M, Hirschi AM. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis1996; 22: 813-18.
24. National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial disk susceptibility tests. Approved standard-7th edn, M2-A7 and (Suppl.)M100-S10 (M2), Vol. 20 No. 1. Wayne. PA: NCCLS, 2000.
25. Cookson BD, Webster M, Phillips I. Control of epidemic methicillin-resistant Staphylococcus aureus. Lancet 1987; I: 696.
26. Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology, 7th edn. Washington, DC: American Society for Microbiology, 1999: 264-82.
27. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-5th edn, M7-A5 and (Suppl.)M100-S10 (M7), Vol. 20 No. 2. Wayne, PA: NCCLS, 2000.
28. Isenberg HD. Essential procedures for clinical microbiology. Washington, DC: American Society for Microbiology, 1998; 235-40.
29. DelVecchio VG, Petroziello JM, Gress MJ et al. Molecular genotyping of methicillin-resistant Staphylococcus aureus via fluorophore-enhanced repetitive-sequence PCR. J Clin Microbiol 1995; 33: 2141-4.
30. de Neeling JA, van Leeuwen WJ, Schouls LM et al. Resistance Staphylococci Netherlands: surveillance an electronic network during 1989-95. J Clin Microbiol 1998; 41: 93-101.
31. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25(Suppl 2): S206-10.